Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2549-2556

  Sallee, Floyd R ^a   Eaton, Katherine ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

2A adrenoceptor agonist; ADHD; Clonidine; Guanfacine; Non stimulant; Psychostimulant

Indexed keywords

GUANFACINE; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; IRRITABILITY; LETHARGY; NAUSEA; PULSE RATE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; UPPER ABDOMINAL PAIN; XEROSTOMIA;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; GUANFACINE; HUMANS; TREATMENT OUTCOME;

EID: 77957087437     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.517523     Document Type: Review

References (49)

1. Castellanos FX, Tannock R. Neuroscience of attention-deficit/ hyperactivity disorder. Nat Rev Neurosci 2002;3:617-628
2. Nigg JT. Neuropsychologic theory and findings in attention-deficit/ hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005;57:1424-1435
3. Sonuga-Barke EJ. Psychological heterogeneity in AD/HD - a dual pathway model of behaviour and cognition. Behav Brain Res 2002;10:29-36
4. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-248
5. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-113
6. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2008. Vital Health Stat 2009;(244):1-81
7. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007;28(4):265-273
8. Cuffe SP, Moore CG, McKeown R. ADHD and health services utilization in the national health interview survey. J Atten Disord 2009;12(4):330-340
9. Pliszka SR. The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005;57:1385-1390
10. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-1384
11. Arnsten AF, Scahill L, Findling RL. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/ hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007;17:393-406
12. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573-603
13. Lang HC, Scheffler RM, Hu TW. The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003-A global pharmaceutical data analysis. Health Policy 2010: published online 10 April 2010, doi:10.1016/j.healthpol.2010.03.005
14. NICE implementation uptake report: Attention deficit hyperactivity disorder (ADHD), management of ADHD in children, young people and adults December 2009. Available from: www.nice.org.uk/media/032/FA/ UptakeReportADHD.pdf [Last accessed 30 June 2010]
15. NICE clinical guideline 72 Attention deficit hyperactivity disorder September Available from: www.nice.org.uk/ CG072 [Last accessed 30 June 2010]
16. Commercial and Pipeline Insight - ADHD; Immature adult market continues to offer greatest commercial potential 2008. Available from: www.companiesandmarkets.com/Summary-Market-Report/30347.asp [Last accessed 6 June 2010]
17. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(Suppl 1):21-31
18. Strattera. Manufacturers Prescribing Information (2008). Indianapolis, IN: Eli Lilly; 2008
19. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007;27(9):1253-1262
20. Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8:4287-4298
21. Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct 2008;4:12
22. Easton N, Shah YB, Marshall FH, et al. Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast. Psychopharmacology 2006;189:369-385
23. Avery RA, Franowicz JS, Studholme C, et al. The alpha-2-A-adrenoreceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000;23:240-249
24. Swartz BE, Kovalik E, Thomas K, et al. The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology 2000;23:263-275
25. Ramos BP, Stark D, Verduzco L, et al. alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 2006;13(6):770-776
26. Wang M, Ramos BP, Paspalas CD, et al. Alpha 2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129(2):397-410
27. Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of representational knowledge: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007;17(Suppl 1):i6-15
28. Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol 1994;62(2):134-139
29. Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport 2003;14(7):1013-1016
30. Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol Psychiatry 2005;57(2):192-195
31. Kiechel J. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980;10(Suppl 1):25S-32S
32. INTUNIV. Manufacturers Prescribing Information (2009). Shire, Wayne, PA; 2010
33. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;29(4):617-625
34. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics 2008;121(1):e73-84
35. Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-165
36. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release, a nonscheduled alpha2A-adrenoceptor agonist, on oppositional symptoms in children aged 6 to 12 years with a diagnosis of attention-deficit/ hyperactivity disorder and the presence of oppositional symptom. CNS Drugs 2010;24(9):755-768
37. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008;13:1047-1055
38. Sallee FR, Lyne A, Wigal T, McGough J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:215-226
39. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-510
40. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985;24(5):617-629
41. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(1):50-54
42. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38(12):1551-1559
43. Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
44. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009;23(Suppl 1):43-49
45. Pliszka SR, Crismon ML, Hughes CW, et al. Texas consensus conference panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45(6):642-657
46. McBurnett K, Pfiffner LJ. Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders. Postgrad Med 2009;121(6):158-165
47. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;121(2):e314-20
48. DellAgnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009;19(11):822-834
49. Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/ hyperactivity disorder clinic. J Child Adolesc Psychopharmacol 2009;19(5):575-582